This collaboration between the pioneer and leader in research and development in gene therapy and the European leader in Artificial Intelligence for mission-critical systems, aims to develop a digital model that will use artificial intelligence to model bioproduction processes and optimize yields.
“Genethon’s Bioprocess development team develops viral vector production processes from the laboratory to an industrial scale. The objective of this collaboration is to evaluate the contribution of artificial intelligence approaches in a bioproduction process to develop one or more efficient digital models of this process (digital representations or digital twins). This will ultimately allow to decipher the impact of certain production parameters on the productivity and the quality of the bio-drugs without having to resort to systematic experimentation,” said Patrick Santambien, Ph.D Technological Development Director at Genethon.
